Jack Slevin
Stock Analyst at Jefferies
(3.96)
# 1,805
Out of 4,988 analysts
43
Total ratings
55.2%
Success rate
19.1%
Average return
Main Sectors:
Stocks Rated by Jack Slevin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVSA Covista | Reiterated: Buy | $175 | $126.72 | +38.10% | 6 | Sep 15, 2026 | |
| MD Pediatrix Medical Group | Downgraded: Hold | $27 → $28 | $25.93 | +7.98% | 5 | Aug 19, 2026 | |
| AHCO AdaptHealth | Upgraded: Buy | $13 | $5.71 | +127.67% | 1 | Jul 21, 2026 | |
| LFST LifeStance Health Group | Reiterated: Buy | $14 | $12.57 | +11.38% | 1 | Jul 16, 2026 | |
| ASTH Astrana Health | Reiterated: Buy | $37 → $53 | $34.36 | +54.25% | 9 | Jun 30, 2026 | |
| AGL agilon health | Upgraded: Buy | $28 → $48 | $89.16 | -46.16% | 8 | May 7, 2026 | |
| USPH U.S. Physical Therapy | Rated: Buy | $102 | $82.47 | +23.68% | 1 | Mar 9, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 → $32 | $19.85 | +61.21% | 6 | Feb 26, 2026 | |
| AMN AMN Healthcare Services | Reiterated: Hold | $22 → $21 | $34.26 | n/a | 4 | Aug 13, 2025 | |
| STLN Starling Oncology | Reiterated: Buy | $2.5 → $2 | $6.96 | n/a | 2 | Jun 10, 2024 |
Covista
Sep 15, 2026
Reiterated: Buy
Price Target: $175
Current: $126.72
Upside: +38.10%
Pediatrix Medical Group
Aug 19, 2026
Downgraded: Hold
Price Target: $27 → $28
Current: $25.93
Upside: +7.98%
AdaptHealth
Jul 21, 2026
Upgraded: Buy
Price Target: $13
Current: $5.71
Upside: +127.67%
LifeStance Health Group
Jul 16, 2026
Reiterated: Buy
Price Target: $14
Current: $12.57
Upside: +11.38%
Astrana Health
Jun 30, 2026
Reiterated: Buy
Price Target: $37 → $53
Current: $34.36
Upside: +54.25%
agilon health
May 7, 2026
Upgraded: Buy
Price Target: $28 → $48
Current: $89.16
Upside: -46.16%
U.S. Physical Therapy
Mar 9, 2026
Rated: Buy
Price Target: $102
Current: $82.47
Upside: +23.68%
Privia Health Group
Feb 26, 2026
Reiterated: Buy
Price Target: $30 → $32
Current: $19.85
Upside: +61.21%
AMN Healthcare Services
Aug 13, 2025
Reiterated: Hold
Price Target: $22 → $21
Current: $34.26
Upside: n/a
Starling Oncology
Jun 10, 2024
Reiterated: Buy
Price Target: $2.5 → $2
Current: $6.96
Upside: n/a